GLP-1 and metabolic health: what the science says, and how nutrition can support it

There is a hormone produced in your gut after every meal that most people have never heard of - until recently. It is called GLP-1, glucagon-like peptide 1, and it does something quietly essential: it signals to the pancreas to release insulin in proportion to blood sugar, tells the brain that food has arrived and appetite can ease, and slows gastric emptying to extend the feeling of fullness. It is one of the body's primary tools for keeping blood sugar balanced and hunger in check after eating.

GLP-1 became widely known because of the pharmaceutical drugs designed to mimic it. But GLP-1 itself is not a drug. It is a hormone the body already makes, in specialised cells lining the gut wall. The more relevant question for anyone interested in metabolic health is not how to replace it pharmaceutically, but what supports the body's own capacity to produce and respond to it naturally.

That is the question the GLP Formula was designed around.

What metabolic balance actually means

Metabolic health is not simply a matter of weight. It refers to how well the body manages blood sugar after meals, how sensitively cells respond to insulin, how effectively fat is used for energy, and how regulated appetite signals are throughout the day. These processes are deeply connected - and they are influenced heavily by the gut microbiome, the liver, and the hormonal signalling systems that link the digestive tract to the brain.

When these systems are working well, blood sugar rises and falls smoothly, hunger is proportionate to real energy needs, and cravings are manageable. When they are less well coordinated — which can happen gradually due to diet, stress, sleep, or age - the signals become less precise and maintaining balance requires more effort.

The GLP Formula brings together five ingredients that each act on a different part of this system.

Akkermansia muciniphila: starting in the gut

Akkermansia muciniphila is a bacterium found in the mucus layer of the gut wall, where it plays an important role in maintaining the intestinal barrier and supporting immune regulation. Higher levels of this bacterium have consistently been observed in people with better metabolic health compared to those with metabolic disorders.

Its connection to GLP-1 is particularly relevant. Akkermansia strengthens gut barrier integrity, reduces the translocation of inflammatory compounds into circulation, and promotes GLP-1 secretion to help improve glycaemic control. It does this partly by producing short-chain fatty acids - metabolic byproducts that bind to receptors on gut cells and stimulate the release of GLP-1 and other satiety hormones. In a randomised proof-of-concept trial in overweight, insulin-resistant adults, pasteurised Akkermansia muciniphila was safe and well-tolerated, and improved insulin sensitivity and total cholesterol compared to placebo. 

The formula uses pasteurised Akkermansia at 15 billion cells - the same form used in published human safety and efficacy research. It is worth noting that large-scale long-term human trials are still developing, and causality in humans has not yet been fully established - but the mechanistic picture and early clinical data are consistent and encouraging.

Berberine: supporting blood sugar balance

Berberine is one of the most studied plant compounds in metabolic research. It is extracted from Cortex Phellodendri and works primarily by activating AMPK - the cellular energy sensor also activated by exercise and fasting - which improves how cells use glucose and respond to insulin, and reduces the liver's tendency to overproduce glucose between meals.

Multiple randomised controlled trials and meta-analyses have confirmed that berberine supports blood sugar balance and improves insulin sensitivity. A 2023 meta-analysis in Frontiers in Pharmacology (Peng et al.), covering 46 randomised controlled trials, found consistent improvements in fasting blood glucose, HbA1c, and insulin resistance markers across the body of evidence. The GLP Formula contains 450 mg of berberine per serving — within the dose range consistently used in the clinical literature.

Saffron: appetite and emotional eating

Saffron's active compounds - safranal and crocin - influence appetite through the serotonergic system. By modulating serotonin availability in the brain, saffron extract appears to reduce the drive to eat in response to emotional or habitual triggers rather than genuine hunger.

A double-blind, randomised, placebo-controlled trial published in Nutrition Research (Gout et al.) found that women taking standardised saffron extract for eight weeks showed a significant reduction in snacking frequency and appetite scores compared to placebo - without changes to overall food intake. The effect was specifically on between-meal eating and emotionally driven food choices, which is where appetite regulation most commonly loses precision. The formula contains 30 mg of saffron extract, within the dose range used in published trials.

EGCg and C3G: fat metabolism and metabolic flexibility

The formula combines two polyphenols that work on fat metabolism through complementary pathways. EGCg - the primary bioactive compound in green tea - activates AMPK, inhibits the enzyme that synthesises new fat from dietary carbohydrates, and supports mitochondrial fat oxidation. Human trials have shown consistent improvements in lipid metabolism, LDL cholesterol, and insulin sensitivity.

C3G - cyanidin-3-glucoside, an anthocyanin from dark berries - improves insulin signalling and supports glucose uptake in muscle tissue through GLUT4 receptor activation. A 2024 review in Food & Function (Zhang et al.) concluded that C3G and EGCg address overlapping but distinct steps in the metabolic pathway, making their combination more comprehensive than either compound alone.

Eriocitrin: glucose support and polyphenol synergy

Eriocitrin is a flavanone from lemon peel that is less well known than the other ingredients, but plays an important dual role in this formula. First, it directly supports glucose metabolism. A double-blind, randomised, placebo-controlled crossover study (Cesar et al., Journal of Medicinal Food, 2022) found that eriocitrin supplementation in people with elevated fasting blood glucose produced a 6% reduction in hyperglycaemia and a 22% increase in circulating GLP-1 levels - suggesting it supports the gut's own production of this hormone naturally.

Second, eriocitrin enhances the activity of other polyphenols consumed alongside it by improving their conversion and absorption through the gut microbiome. In this formula, that means it supports the effectiveness of both EGCg and C3G - making the combination more than the sum of its parts.

Who this is relevant for

The GLP Formula is designed for adults who want to support metabolic balance as part of a broader approach to health. It is relevant for people who notice that appetite regulation feels less precise - more frequent cravings, slower satiety, energy variability after meals. It is also well suited to people actively working to improve diet quality who want nutritional support for the underlying metabolic processes involved.

It is not a substitute for medical advice or treatment. Anyone with an existing health condition, who takes medication, or who is pregnant or breastfeeding should consult a healthcare professional before use.

A note on the science

Each ingredient in the GLP Formula has its own published research base. The combination reflects a coherent logic: gut barrier and GLP-1 support from Akkermansia, glucose metabolism from berberine, appetite regulation from saffron, fat metabolism from EGCg and C3G, and glucose support plus polyphenol synergy from eriocitrin. These pathways intersect and reinforce each other - which is why a multi-ingredient approach is more meaningful here than any single compound alone.

This product is a food supplement. It is not intended to diagnose, treat, cure, or prevent any disease. Food supplements should not be used as a substitute for a varied and balanced diet and a healthy lifestyle.

Scientific sources

• Aja E et al. (2025). Health effects and therapeutic potential of the gut microbe Akkermansia muciniphila. Nutrients.
• Arukha AP et al. (2025). Effect of Akkermansia muciniphila on GLP-1 and insulin secretion. Nutrients.
• Cesar TB et al. (2022). Nutraceutical eriocitrin (Eriomin) reduces hyperglycemia by increasing glucagon-like peptide 1 and downregulates systemic inflammation. Journal of Medicinal Food.
• Gout B et al. (2010). Satiereal, a Crocus sativus L. extract, reduces snacking and increases satiety in a randomized placebo-controlled study. Nutrition Research.
• Peng L et al. (2023). Berberine and its effects on glycaemic control: a meta-analysis of randomized controlled trials. Frontiers in Pharmacology.
• Zhang Y et al. (2024). Cyanidin-3-glucoside in metabolic health: mechanisms and clinical evidence. Food & Function.